1. COVID-19 situation report-73. World Health Organization website. (2020)
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. [
DOI:10.1016/S0140-6736(20)30566-3]
3. Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. Jama. 2013;309(3):275-82. [
DOI:10.1001/jama.2012.194139] [
PMID]
4. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09. BMC Infecti Dis. 2018;18(1):1-20. [
DOI:10.1186/s12879-018-3548-0] [
PMID] [
PMCID]
5. Zheng Z, Chen R, Li Y, Liu X, He W, Xu Y, et al. The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome. Chin J Respir Crit Care Med. 2003;2(5):270-4.
6. Rijnders BJ, Schauwvlieghe AF, Wauters J. Influenza-associated pulmonary aspergillosis: a local or global lethal combination?. Clin Infect Dis. 2020. [
DOI:10.1093/cid/ciaa010] [
PMID] [
PMCID]
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
8. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. [
DOI:10.1016/S2213-2600(20)30079-5]
9. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020.
10. Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19?. Arch Med Res. 2020;51(7):741-2.
11. Novy E, Scala-Bertola J, Roger C, Guerci P. Preliminary therapeutic drug monitoring data of β-lactams in critically ill patients with SARS-CoV-2 infection. Anaesth Crit Care Pain Med. 2020;39(3):387-8. [
DOI:10.1016/j.accpm.2020.04.005] [
PMID] [
PMCID]
12. Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020;56(2):106053. [
DOI:10.1016/j.ijantimicag.2020.106053] [
PMID] [
PMCID]
13. Min JY, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators of inflamm. 2012;2012. [
DOI:10.1155/2012/649570] [
PMID] [
PMCID]
14. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: Will this be the way forward?. Biosci Trends. 2020. [
DOI:10.5582/bst.2020.03058] [
PMID]
15. Bosseboeuf E, Aubry M, Nhan T, De Pina JJ, Rolain JM, Raoult D, et al. Azithromycin inhibits the replication of Zika virus. J Antivir Antiretrovir. 2018;10(1):6-11. [
DOI:10.4172/1948-5964.1000173]
16. Wang M, Wei H, Zhao Y, Shang L, Di L, Lyu C, et al. Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China. Bosnian J Basic Med Sci. 2019;19(1):86. [
DOI:10.17305/bjbms.2018.3826] [
PMID] [
PMCID]
17. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 ;26(12):1622-9. [
DOI:10.1016/j.cmi.2020.07.016] [
PMID] [
PMCID]
18. Castilho SR, Godoy CS, Guilarde AO, Cardoso JL, André MC, Junqueira-Kipnis AP, et al. Acinetobacter baumannii strains isolated from patients in intensive care units in Goiânia, Brazil: Molecular and drug susceptibility profiles. PLoS One. 2017;12(5):e0176790. [
DOI:10.1371/journal.pone.0176790] [
PMID] [
PMCID]
19. Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2):4-2. [
DOI:10.1128/microbiolspec.VMBF-0016-2015] [
PMID] [
PMCID]
20. Manchanda V, Sanchaita S, Singh NP. Multidrug resistant acinetobacter. J Glob Infect Dis. 2010;2(3):291. [
DOI:10.4103/0974-777X.68538] [
PMID] [
PMCID]
